Alzheimer's Society responds to EMA rejection of aducanumab
The European Medicines Agency (EMA) has recommended that aducanumab, marketed as Aduhelm, is not approved for use across the EU. The drug was previously approved for use in the US by the Food and Drug Administration (FDA) on 7 June 2021.
Dr Richard Oakley, Associate Director of Research at Alzheimer’s Society, said:
'It will be disappointing for people with dementia to hear today’s decision on aducanumab.
There have been no new treatments for Alzheimer’s disease in such a long time.
'But that makes it even more important any new drugs for dementia have the data to back up that they’re both safe and effective.
'Aducanumab may be the first drug that aims to slow down Alzheimer’s disease to reach this stage, but it’s certainly not the last – there are 125 other drugs currently in clinical trials.
'Research transformed HIV and cancer, it can stop dementia in its tracks too, but we’ll need the Government to hold its promise to double dementia research funding to make this a reality.'
What is Aducanumab?
Find out more about the drug, which the FDA approved for clinical use for people living with Alzheimer's disease in the USA back in June 2021.